In Re Glumetza Antitrust Litigation

  1. February 04, 2022

    Final Approval In Glumetza Antitrust Deal Gives Attys $50M

    A California federal judge granted final approval of three settlements resolving direct buyers' class claims that drugmakers plotted to delay the generic version of the blockbuster diabetes drug Glumetza, awarding $50 million in attorney fees to class counsel, less than half of the $112.8 million they had sought.

  2. January 20, 2022

    Alsup Mulls $113M Atty Fees In $454M Glumetza Antitrust Deal

    U.S. District Judge William H. Alsup said on Thursday he will grant final approval to $454 million in settlements resolving direct Glumetza buyers' class claims that drugmakers plotted to delay the generic version of the blockbuster diabetes drug, but said he's still weighing attorneys' $112.8 million fee bid.

  3. December 02, 2021

    Attys Seek $113M In Fees From Glumetza Buyers' $454M Deal

    A class of direct Glumetza buyers who scored $454 million in settlements that will end several claims that drugmakers plotted to delay the generic version of the blockbuster diabetes drug asked a California federal court Wednesday to award plaintiffs' attorneys $112.8 million in fees and $2.4 million in costs.

  4. September 22, 2021

    Pharma Giants' $454M Glumetza Antitrust Deal Gets Initial OK

    U.S. District Judge William Alsup preliminarily approved $454 million in settlements Wednesday resolving direct buyers' allegations that Bausch Health Cos. Inc., Lupin Pharmaceuticals Inc. and Assertio Therapeutics Inc. plotted to delay the blockbuster diabetes drug Glumetza's generic version, but warned the parties not to make it difficult for class members to opt out.

  5. September 20, 2021

    Lupin Will Pay $150M To End Glumetza Antitrust Suit

    Direct buyers of blood sugar medication Glumetza on Monday inked a $150 million deal in California federal court with Lupin Pharmaceuticals, which is accused of taking part in a scheme to stave off the launch of a generic version of the blockbuster drug.

  6. September 09, 2021

    Pharma Giants Ink $300M Deal To End Glumetza Antitrust Suit

    Direct buyers of Glumetza are floating a $300 million deal in California federal court with Bausch Health and several subsidiaries accused of plotting to stave off the blockbuster blood sugar drug's generic version.

  7. September 02, 2021

    IP Forecast: Herman Miller Readies For Chair TM Fight

    Furniture giant Herman Miller Inc. will argue next week in favor of showing California jurors in an upcoming trade dress trial that its Aeron office chair was illustrious enough to be featured in "The Simpsons" and "Casino Royale," while a rival is set to challenge the use of the media clips. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.

  8. September 03, 2020

    Humana's Glumetza Suit Too Little, Too Late, Court Told

    Drugmakers battling antitrust claims that they agreed to block a generic version of blood sugar drug Glumetza urged a California federal judge Wednesday to gut Humana Inc.'s lawsuit, arguing the insurer's complaint, filed nearly a year after the first class actions, is unclear and many allegations are outside the statute of limitations.

  9. August 17, 2020

    Glumetza Buyers Get Cert. In Suit Over 800% Price Jump

    A California federal judge on Friday certified a proposed class of diabetes drug buyers who accuse drugmakers of violating antitrust laws by blocking a generic version of Glumetza, saying it will be "most engaging" to see how counsel argues that a 800% price hike served competition.

  10. August 06, 2020

    Retailers Face Uphill Fight For Cert. In Glumetza Price-Fix Suit

    U.S. District Judge William Alsup appeared skeptical on Thursday of a bid to certify a class of retailers who accuse drugmakers of violating antitrust laws by blocking a generic version of the diabetes drug Glumetza, saying he can't "kick the can down the road" and ignore potential proof of harm differences.